[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco-dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco-dependence":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,52,85,112,137,162,181,203,229,254,275,297,320,340,368],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100590357","phase-4-varenicline-for-smoking-reduction-in-veterans-not-ready-to-quit-100590357",false,"NCT06966362","Varenicline for Smoking Reduction in Veterans Not Ready To Quit","Varenicline for Smoking Reduction in Veterans Unwilling to Quit","Inclusion Criteria:\n\n* Report smoking an average of 5 or more cigarettes daily for the previous 6 months\n* Not ready to set a quit date in the next 30 days but willing to cut down on their smoking\n* Able to read, write, and speak English\n* Be medically eligible to use study medications (NRT or varenicline)\n* If female, use an approved method of birth control while using study medication\n* Be at least 21 years old\n* Be a Veteran\n\nExclusion Criteria:\n\n* Unable to give informed, voluntary consent to participate\n* Current use of any pharmacotherapy for smoking cessation\n* Use of non-cigarette tobacco products as primary form of tobacco use\n* Incarceration","ALL","21 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.",[26,27,28,29],"Veterans","Tobacco Use Disorder","Cigarette Smoking","Tobacco Dependence",[31,32,26,33,34,35,36,37,38],"Varenicline","Tobacco use disorder","Quit attempts","Cigarette smoking","Motivation phase treatment","Nicotine replacement therapy","Smoking reduction","Smoking abstinence","NOT_YET_RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":20},"2026-07-20",{"date":47,"type":20},"2030-06-28",{"name":49,"class":50},"VA Office of Research and Development","FED",4,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100553619","effect-of-yoga-on-reducing-craving-in-tobacco-dependent-individuals-100553619","NCT06488443","Effect of Yoga on Reducing Craving in Tobacco Dependent Individuals","Randomized Control Study to Study the Effect of Yoga on Reducing Craving in Tobacco Dependent Individuals Who Want to Quit Tobacco Use","Inclusion Criteria:\n\n* -Tobacco dependent individuals (Fagerstrom test for tobacco dependence score more than or equal to 4)\n\n  * -Men aged 18 to 65 years\n  * -Recruited from Rural community health and training centre, Mugalur, Tobacco cessation centre and OPDs of Department of general medicine, pulmonary medicine, cardiology, oncology, ENT and dental surgery and other superspeciality OPD at SJMCH\n\nExclusion Criteria:\n\nPatients with recent alcohol use (last 3 months) and use of other drugs of abuse\n\n* -Patients with clinical diagnosis of Intellectual disability\n* -Comorbid Major mental illness including Dementia, Psychosis, Recurrent depressive disorder, Bipolar affective disorder, OCD, generalized anxiety disorder, Panic disorder and Phobias, diagnosed within the last 6 months.\n* -Patients with recent MI and stroke in the last 3 months or those physically unable to perform the yoga postures due to physical disabilities determined by clinical interview.\n\n  * -Patients with severe hypertension(SBP≥180mmHg and BP≥120mmHg)\n  * -Patients with seizures disorder\n  * -Patients with COPD(GOLD-2,3 and 4)","MALE","18 Years","65 Years",{"count":63,"type":20},96,[65],"NA","Yoga is a culturally acceptable practice that can reduce craving and help people quit tobacco. There is a need to evaluate the feasibility of implementation of a well- designed yoga protocol to address craving in individuals who use tobacco in India.",[29],[69,70,71,72],"Tobacco dependence","Smoking","Craving","Fagerstorm test","RECRUITING","2026-06-03",{"date":76,"type":43},"2026-06-05",{"date":78,"type":43},"2024-11-01",{"date":80,"type":20},"2027-05-31",{"name":82,"class":83},"University of Pittsburgh","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":60,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100589308","chatbot-for-online-support-groups-to-treat-tobacco-addiction-100589308","NCT06952725","Chatbot for Online Support Groups to Treat Tobacco Addiction","Intelligent Chatbot for Online Support Groups to Treat Tobacco Addiction","Inclusion Criteria:\n\n* Cigarette smokers (can also use e-cigarettes)\n* Ages 18-75 years\n* English speaking\n* Smart phone with unlimited data\n* 100 cigarettes lifetime\n* Prepared to quit smoking within 10 days of study start\n* Active text and email\n* Use of social media or group messaging\n* Home address provided\n* Contact information for a collateral provided\n* Setup of a GroupMe account for study\n\nExclusion Criteria:\n\n* No NRT health contraindications\n* 5+ cigarettes per day\n* Not an illicit drug user\n* Not a daily marijuana\u002Fcannabis user",true,"75 Years",{"count":95,"type":20},120,[65],"Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.",[29,27],[100,101,102],"tobacco use addiction","online support group","chatbot","2026-05-20",{"date":105,"type":43},"2026-05-22",{"date":107,"type":20},"2026-12-01",{"date":109,"type":20},"2028-06-01",{"name":111,"class":83},"University of California, Irvine",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":84},"100597506","phase-3-semaglutide-for-smoking-cessation-in-patients-with-diabetes-100597506","NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial","GLP1-SC","Inclusion Criteria:\n\n* Adults (18 years or older) with type 2 diabetes\n* Currently residing in Ontario\n* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months\n* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.\n* Have not used GLP-1 receptor agonists in the past six months.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Contraindication to NRT or GLP-1 RA.\n* Current daily use of NRT or a GLP1 RA.\n* Use of bupropion, cytisine, and varenicline within the last 7 days.\n* Use of a DPP-IV inhibitor within the last 7 days.\n* Initiation of a new diabetes medication within the last 3 months.\n* As per the product monograph, participants with the following diagnoses or disorders will be excluded;\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2\n* Diabetic ketoacidosis\n* Type I diabetes\n* Acute pancreatitis or pancreatic cancer\n* Acute, chronic or end-stage renal failure\n* Tachyarrhythmias\n* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).\n* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).",{"count":121,"type":20},100,[123],"PHASE3","To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.",[126,127,29],"Diabetes Mellitus, Type 2","Nicotine Addiction","2026-05-05",{"date":130,"type":43},"2026-05-11",{"date":132,"type":43},"2026-02-13",{"date":134,"type":20},"2027-07",{"name":136,"class":83},"Ottawa Heart Institute Research Corporation",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":84},"100532841","phase-2-cannabidiol-for-reducing-cigarette-use-100532841","NCT06218056","Cannabidiol for Reducing Cigarette Use","Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use","Inclusion Criteria:\n\nThe investigators will study equal numbers of males and females betweeen 18 - 65 years of age who have Tobacco Use Disorder and express a desire for smoking cessation. Participants will be recruited from the clientele base at Cri-Help Treatment Center in North Hollywood, CA, where the investigators have a long-standing relationship and where the investigators have conducted other research protocols. This study will be conducted at Cri-Help Treatment Center.\n\nParticipants will not be recruited from the general population for this study because common use of cannabis in the greater Los Angeles area would confound measurements of CBD, interfering with evaluation of the association of plasma level from treatment with efficacy. This problem is avoided in studying participants who are receiving treatment at a facility where cannabis use is not allowed.\n\nThe investigators will include all racial and ethnic groups. Based on the population of the surrounding communities in the Los Angeles region, the investigators anticipate a racial and ethnic makeup of approximately 26% White, 9% Black\u002FAfrican American, 49% Hispanic\u002FLatino, 14% Asian American, and 2% multi-racial\u002Funknown. These percentages align with our recent studies.\n\nSmoking cigarettes and at least moderate nicotine dependence, as indicated by smoking 5 or more cigarettes per day and\u002For a score of at least 4 on the Fagerström Test for Nicotine Dependence are inclusion criteria. Although vaping is popular and a high proportion of participants who vape also report cigarette smoking (58%), the investigators will exclude participants who vape nicotine. Vaping is not allowed at Cri-Help, Inc.\n\nExclusion Criteria:\n\n* Physiological dependence on alcohol or any drug, requiring medical detoxification and\u002For showing signs of acute withdrawal symptoms from opioids, alcohol or benzodiazepines.\n* Treatment of Opioid Use Disorder with buprenorphine or methadone to avoid potential drug-drug interactions. CBD interacts with CYP3A. Opioid drugs metabolized by cytochrome P450 (CYP450), and cytochrome P450 isoenzyme CYP3A4 (CYP3A4) in particular, include fentanyl, methadone, oxycodone, and buprenorphine.\n* Meeting DSM-5 criteria for schizophrenia, Bipolar I disorder, psychotic disorder, having active suicidal ideation, or suicide attempt in the past 12 months. NOTE: Participants with other psychiatric conditions, such as major depression, generalized anxiety, dysthymia, social phobia or specific phobia can enroll if they are clinically stable.\n* AIDS or current HIV medication treatment with antiviral and\u002For non-antiviral therapy (due to the interaction of CBD with antiviral therapy).\n* Clinically significant abnormalities on EKG (such as evidence of arrhythmia or MI).\n* Clinically significant cardiovascular, hematologic, hepatic, renal, neurological, or endocrine abnormalities \\[specific exclusion criteria: AST greater than or equal to 3Xs ULN, Bilirubin greater or equal to 1.5 X ULN, Prothrombin time\u002FInternational Normalized Ratio (INR) \\> 1.5.\n* Pregnancy and\u002For lactation. Contraception methods required at time of enrollment, and throughout the duration of the study medication period include abstinence, oral contraceptives, depot contraceptives, condom with spermicide, cervical cap with spermicide, diaphragm with spermicide, intrauterine device, surgical sterilization (e.g. tubal ligation, vasectomy).\n* Because of evidence that CBD affects ovarian function in rats, women with values outside the reference ranges on a hormonal battery \\[estradiol, follicle- stimulating hormone, free thyroxine index, luteinizing hormone, prolactin, total T3 and total T4, thyroid-stimulating hormone\\], followed by an abnormal ovarian ultrasound finding will be excluded.\n* Based on data obtained using Epidiolex® (CBD) oral solution label section 7, \"Drug Interactions\", the investigators will exclude participants who are taking the following medications: a) strong inducers of CYP3A4 or CYP2C19, which may decrease CBD plasma levels; and b) substrates of UGT1A9, UGT2B7, CYP2B6, CYP2C19 due to the potential of CBD to inhibit enzyme activity.",{"count":95,"type":20},[146],"PHASE2","The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential.\n\nThe investigators will recruit participants from CRI-Help, Inc., a substance abuse treatment program in North Hollywood, where residents who indicate the desire to stop smoking are prohibited from using other cannabis products which would affect recruitment.\n\nThe aims of this study are:\n\n1. Evaluate the effects of CBD on nicotine intake.\n2. Exploratory Aims. Measure plasma concentrations of CBD, N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) at baseline and day 7.\n\nParticipants who meet eligibility criteria will take part in a 56-day treatment phase during which they receive the study medication under supervision (CBD or placebo twice daily) and complete questionnaires on side effects, withdrawal, craving and mood symptoms. Blood, breath, and urine tests will also be performed throughout the study. Participants who complete the treatment will also be assessed at 1-month and 3-month follow up visits.",[27,149,29],"Tobacco Smoking",[151,27,152],"Cannabidiol","Smoking Cessation","2026-04-06",{"date":155,"type":43},"2026-04-13",{"date":157,"type":43},"2024-10-31",{"date":159,"type":20},"2026-12-31",{"name":161,"class":83},"University of California, Los Angeles",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":92,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":84},"100355761","phase-3-early-withdrawal-exposure-and-negative-affect-withdrawal-naw-regulation-training-for-smoking-cessation-100355761","NCT03912194","Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation","Inclusion Criteria:\n\n* at least 18 years of age\n* smoke at least 5 cigarettes per day\n* Expired breath carbon monoxide (CO) reading of at least five parts per million\n* report the intention to quit\n* reside in the Birmingham area with no plan to relocate outside of the area in the next 6 months\n* access to a telephone\n\nExclusion Criteria:\n\n* inability to speak English\n* presence of a condition that contraindicates use of the nicotine patch\n* presence of conditions that might interfere with compliance with the protocol or greatly complicate treatment\n* any acutely life-threatening disease\n* concurrent participation in a formal treatment program for smoking cessation\n* current use of any pharmacotherapy for smoking cessation",{"count":19,"type":20},[123],"Smoking remains the single most preventable cause of morbidity and mortality in the United States, accounting for approximately half a million deaths every year. The current study will investigate the efficacy and mechanisms of change of a novel smoking cessation intervention. The current study will thus provide essential information regarding a treatment that has the potential to enhance the efficacy of existing smoking cessation interventions, thereby having a beneficial impact on the public health of the United States.",[29],"2026-03-09",{"date":174,"type":43},"2026-03-11",{"date":176,"type":43},"2019-08-01",{"date":178,"type":20},"2026-07-01",{"name":180,"class":83},"University of Alabama at Birmingham",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":188,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":84},"100609882","phase-4-c-raven-a-virtual-tobacco-cessation-intervention-in-residency-clinics-100609882","NCT07220356","C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics","C-Raven: Pilot RCT of an Avatar-delivered Computerized Intervention for Tobacco Cessation With Community Health Worker Linkage to Lung Cancer Screening in Baltimore City (FY26)","Inclusion Criteria:\n\n* Age 50 or older\n* Current tobacco use with \\>100 cigarettes smoked in the participant's lifetime\n* Considering smoking cessation\n* Planning to remain in local area for at least 6 months\n* English speaking (intervention currently in English only)\n\nExclusion Criteria:\n\n* Contraindication to nicotine replacement therapy\n* Current engagement in formal smoking cessation program\n* Major cognitive or psychiatric impairment\n* Severe hearing impairment\n* Investigator discretion","50 Years",{"count":190,"type":20},30,[23],"In a residency clinic in Baltimore, the investigators propose to conduct a pilot RCT comparing a) an avatar-delivered computerized intervention (CI) for tobacco cessation augmented with CHW support and navigation to lung cancer screening to b) a waitlist control.\n\nWith a sample of participants from the residency clinic (N=30), the investigators will collect data on feasibility of recruitment, intervention engagement and completion, and short-term smoking cessation outcomes. Individuals will be assessed at baseline, 1 month, 3 months, and 6 months. The investigators will conduct interviews with a subset of pilot participants to collect qualitative data on intervention acceptability.",[29],"2026-01-30",{"date":196,"type":43},"2026-02-02",{"date":198,"type":43},"2025-12-10",{"date":200,"type":20},"2027-06-30",{"name":202,"class":83},"Johns Hopkins University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100557845","harm-reduction-for-smokers-with-mental-illness-100557845","NCT06543407","Harm Reduction for Smokers With Mental Illness","Harm Reduction for Smokers With Mental Illness: RCT of E-cigarette Provision With or Without Behavioral Support to Boost Switching","Diagnostic Criteria (must have one to be eligible):\n\n* Schizophrenia\n* Bipolar disorder\n* Major Depressive Disorders\n* Posttraumatic disorder\n* Other anxiety disorders\n\nAdditional Inclusion Criteria:\n\n* 21 years or older;\n* English-speaking;\n* Daily smoker (at least 10 cigarettes\u002Fday);\n* At least one quit attempt in the past 5 years using evidence- based pharmacotherapy or behavioral cessation support;\n* Not currently interested in quitting.\n\nExclusion Criteria:\n\n* Currently residing in a nursing home;\n* Current diagnosis of Asthma;\n* Cognitive impairment (score \\\u003C26 on the Telephone Interview for Cognitive Status (TICS);\n* Current use of e-cigarettes (\\>once a week);\n* Psychiatric instability (hospitalized in the past month);\n* Current AND moderate to severe substance use disorder;\n* Pregnant or planning to become pregnant;\n* Use of any smoked products other than cigarettes;\n* Current unstable medical illness making e-cigarette unsafe (e.g., recent heart attack, cancer);\n* Participation in SWITCH IT pilot study.",{"count":211,"type":20},250,[65],"To compare the efficacy of e-cigarette (e-cig) provision with or without behavioral support (SWITCH IT) delivered via telehealth to reduce harm among smokers with MI who cannot quit smoking and are not ready to pursue cessation treatment, and to examine self-regulation (using e-cigs instead of cigarettes to cope with stress\u002Fdistress and self-efficacy) as a potential mechanism for behavior change from SWITCH IT",[29],[216,217,218],"serious mental illness","harm reduction","e-cigarettes","2026-01-13",{"date":221,"type":43},"2026-01-15",{"date":223,"type":43},"2024-10-01",{"date":225,"type":20},"2028-03-31",{"name":227,"class":83},"Dartmouth-Hitchcock Medical Center",2,{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":92,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":84},"100473508","phase-1-oral-cannabidiol-for-tobacco-cessation-100473508","NCT05445804","Oral Cannabidiol for Tobacco Cessation","Inclusion Criteria:\n\n1. Have provided written informed consent\n2. Be between the ages of 18 and 65\n3. Report use of \\> 10 cigarettes per day for \\> 1 year with smoking status verified by either a positive breath carbon monoxide test (\\>8ppm) or urine cotinine test (\\>200ng\u002FmL) at screening\n4. Report interest in quitting tobacco in the next two months\n5. Are willing to engage in a series of practice quit attempts as part of the study.\n6. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests as determined by a licensed medical professional.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration. Acceptable forms of contraception include: double barrier contraception or a combination of a barrier contraception and a hormonal implant, injectable, combined oral contraceptive, or a male partner who has had a vasectomy; intrauterine device or tubal ligation.\n\nExclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders\n2. Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation\n3. Test positive for drugs of abuse (except nicotine) and\u002For breath alcohol test at study admission\n4. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity.\n5. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n6. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding.\n7. Use of an over the counter, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant\n8. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce\u002Finhibit CYP3A4 enzymes.\n9. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina).\n10. Have elevated serum liver transaminase (AST or ALT) above 2 x upper limit of normal, or elevated bilirubin above 1.5 x upper limit of normal.\n11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.\n\n    \\-",{"count":236,"type":20},50,[238],"PHASE1","Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.",[241,149,29,27,242],"Tobacco Use","Tobacco Use Cessation",[244,70,151,245],"Tobacco","CBD","2026-01-05",{"date":248,"type":43},"2026-01-07",{"date":250,"type":43},"2022-11-01",{"date":252,"type":20},"2027-02-01",{"name":202,"class":83},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":273,"locationsCount":84},"100604339","phase-4-extended-intervention-for-tobacco-use-exit-for-people-experiencing-homelessness-100604339","NCT07148232","Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Able to understand study procedures and to comply with them for the entire length of the study.\n3. Ability of individual to understand a written informed consent document, and the willingness to sign it.\n4. Staying at the recruitment site and meeting criteria for homelessness as defined by the Homeless Emergency and Rapid Transition to Housing Act.\n5. Current smoking (smoking at least 5 cigarettes per day (cpd), verified via expired carbon monoxide (CO) \\>= 8 ppm using Micro+pro Smokerlyzer).\n6. Having an intention to quit smoking within the next six months.\n7. English speaking.\n\nExclusion Criteria:\n\n1. Contraindication to any study-related procedure or assessment.\n2. Reasons that preclude the use of nicotine replacement therapy (NRT) (e.g., pregnancy or myocardial infarction in the past two weeks).",{"count":261,"type":20},150,[23],"This study is investigating tobacco use and providing tobacco treatment among people experiencing homelessness in California, in San Francisco and Los Angeles.",[265,266,241,242,29],"Tobacco Cessation","Tobacco Abstinence","2025-11-19",{"date":269,"type":43},"2025-11-21",{"date":271,"type":43},"2025-11-14",{"date":200,"type":20},{"name":274,"class":83},"University of California, San Francisco",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":228},"100519424","use-of-nicotine-pouches-among-daily-smokers-100519424","NCT06043362","Use of Nicotine Pouches Among Daily Smokers","Randomized Placebo-controlled Trial of Nicotine Pouches in Smokers","Inclusion Criteria:\n\n* Commonly smoke ≥ 5 cigarettes per day (at least 2 days\u002Fweek) for at least the prior 12 months\n* Exhaled CO measurement of ≥ 6 parts per million at baseline\n* Must be interested in reducing cigarette consumption by at least 50% and willing to try nicotine pouches\n* Able to understand, read and write in English\n* Access to e-mail and a smartphone\u002Fcomputer that has reliable internet connection\n* Able to understand and give informed consent\n\nExclusion Criteria:\n\n* Plans to quit smoking within the next 30 days\n* Currently pregnant, breastfeeding, or planning to become pregnant in the next 6 months\n* Recent (past 3 months) unstable illness that may increase risks of participation or ability to participate fully (e.g. hospitalization for a mental health condition or substance use disorder in prior 6 months, stroke or myocardial infarction in the past year)\n* Serious current respiratory diseases (e.g. exacerbations of asthma or chronic obstructive pulmonary disease \\[COPD\\], requiring oxygen or oral prednisone), kidney disease (e.g. requiring dialysis), liver disease (e.g cirrhosis), or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n* Use of a nicotine pouch or other non-cigarette nicotine product (e-cigarette, pipe, cigar, chew, snus, hookah, IQOS) for 5 or more days in the past 28 days\n* Use of illegal drugs daily or weekly in the past 3 months\n* Use of combustible (smoked) recreational or medical marijuana weekly in the past 3 months (less frequent smoked medical marijuana or use of other forms of medical marijuana are ok)\n* Other member of the household currently participating in the study\n* Any other condition that in the opinion of the investigator would make it unlikely that the participant could comply with the study protocol","70 Years",{"count":284,"type":20},375,[65],"The purpose of this clinical trial is to understand the health effects of a new oral nicotine pouch, and also to understand if this product can help reduce traditional cigarette smoking. The main aims are:\n\n1. Understand the impact of nicotine pouch use on toxicant exposure biomarkers, and indicators of potential harms to health.\n2. Examine the influence of nicotine pouch use on conventional tobacco product use (cigarettes).\n\nParticipants will be randomized to one of six nicotine pouch groups (3 nicotine strengths, each with 2 potential flavors) to use over 16 weeks and asked to reduce their cigarette smoking over that time by at least 75% by substituting with the use of the nicotine pouches. Researchers will compare the outcomes of the different nicotine pouch strengths and flavors to each other. Participants will be asked to complete study questionnaires and provide urine, exhaled carbon monoxide, and mouth cell samples, and other health measurements.",[29],"2025-09-26",{"date":290,"type":43},"2025-10-01",{"date":292,"type":43},"2024-09-17",{"date":294,"type":20},"2028-08",{"name":296,"class":83},"Milton S. Hershey Medical Center",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":84},"100583802","reach-through-equitable-implementation-in-utah-100583802","NCT06881069","Reach Through Equitable Implementation in Utah","Reach Through Equitable Implementation in Utah (REI-UT)","REI-UT","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Speak English or Spanish\n* Currently use tobacco\n* Live in a persistent poverty census tract\n* Present at participating clinics\n* Valid cell phone number in the electronic health record (EHR)\n* Electronic health records indicate they have not opted out of receiving text contact from the clinic\n\nExclusion Criteria:\n\n* Opt-out of study",{"count":306,"type":20},1560,[65],"The goal of this pragmatic, multilevel Type III Hybrid Effectiveness-Implementation trial is to increase the reach of existing evidence-based interventions (EBIs) for tobacco cessation and to mitigate the impact of adverse Social Drivers of Health (SDOH) among safety-net healthcare system patients who live in persistent poverty (PP) census tracts.\n\nAim 1: Test the ability of patient-level Conversational Agents (CA) \\& Patient Navigation (PN) dissemination strategies to increase the Reach (primary outcome) of evidence-based tobacco cessation treatment delivered via the Utah Tobacco and Nicotine Quit Services (Quit Services) among Community Health Center (CHC) patients who use tobacco and live in persistent poverty census tracts. Secondary analyses will examine the outcome of Reach of services for SDOH among these patients and will evaluate both 1) patient-level CA and PN dissemination strategies and 2) a clinic-level implementation strategy using a pre-post design.\n\nAim 2: Explore contextual factors (e.g., clinic size, patient composition, rurality, patient demographics) related to the Reach, Adoption, Implementation, and potential Maintenance of strategies.\n\nAim 3: Determine the cost-effectiveness of clinic and patient-level strategies based on Quit Services enrollment and service receipt for SDOH.\n\nThis trial implements a clinic-level implementation strategy, Ask-Advise-Connect (AAC), to address tobacco cessation and needs around social drivers of health for patients in all participating clinics. Eligible patients who are not enrolled in Quit Services four weeks after the clinical encounter, will receive text messages from a chatbot offering information and connections to the Quit Services and patient navigation support from a Community Health Worker.",[242,241,149,310,29],"Tobacco Chewing","2025-03-11",{"date":313,"type":43},"2025-03-18",{"date":315,"type":43},"2025-02-13",{"date":317,"type":20},"2028-01-30",{"name":319,"class":83},"University of Utah",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":92,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":21,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":84},"100529181","smoke-free-home-study-in-subsidized-housing-100529181","NCT06170437","Smoke-free Home Study in Subsidized Housing","Healthy Homes Study: A Protocol for a Place-based Smoke-free Home Intervention in Federally Subsidized Housing","Inclusion Criteria:\n\nEligible resident participants\n\n* Current smokers defined as:\n\n  * Smoked at least 100 cigarettes in lifetime\n  * Smoked daily in the past 7 days, and at least 5 cigarettes per day, verified by expired CO ≥ 5 parts per million \\[ppm\\] Smokerlyzer CO+ monitor),\n  * Smoke in their home\n* Expect to live in the subsidized housing site for at least 12 months\n* Age ≥ 18 years\n* Speak Chinese (Cantonese or Mandarin), English, Spanish, or Vietnamese\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Contraindication to any study-related procedures or assessment",{"count":328,"type":20},544,[65],"Comprehensive smoke-free policies have the potential to substantially reduce tobacco-related disparities among populations in subsidized housing. This study fills this gap by identifying approaches to increase the implementation of smoke-free policies in all types of subsidized housing by increasing the voluntary adoption of smoke-free homes and promoting access to smoking cessation services.",[29,149],"2025-02-20",{"date":334,"type":43},"2025-02-24",{"date":336,"type":43},"2024-07-12",{"date":338,"type":20},"2027-08-31",{"name":274,"class":83},{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":228},"100566169","smoking-cessation-intervention-including-health-navigators-to-address-unmet-social-needs-of-parents-who-smoke-100566169","NCT06651684","Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","A Randomized Controlled Trial of a Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke","CanCEASE-2","Inclusion Criteria:\n\n* Parents or legal guardians aged ≥18 years, with child(ren) aged 0-17 years, attending a regular scheduled medical appointment in one of the study sites.\n* Smokers with at least one self-reported social risk as assessed by validated screening questions on the domains employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy.\n* Sufficiently proficient in French or English to understand and complete study questionnaires.\n\nExclusion Criteria:\n\n* Families presenting at the clinic for an urgent medical issue.\n* Parents without at least one social risk.\n* If both parents smoke, only one parent will be eligible to participate.",{"count":349,"type":20},1000,[65],"Background: The goal of this study is to address parental smoking and social adversity, which can present an obstacle for smoking cessation, in order to decrease childhood exposure to second-hand cigarette smoke. To address these factors, this study includes a smoking cessation intervention for parents and legal guardians recruited in pediatric clinics (CanCEASE), as well as the support of a Health Navigator (HN) to work with the participant towards the resolution or mitigation of unmet social needs.\n\nParticipants: The research team will recruit one thousand participants from pediatric outpatient clinics within two healthcare centres in and around the city of Montreal, Canada, over the course of 2.5 years. Eligible persons are parents and legal guardians, of any sex and gender, accompanying children under 18 to their scheduled medical appointments, and who report at least one social risk in selected areas (i.e., employment, housing stability, ability to pay for utilities, financial resource strain, food security, transportation, childcare, parent education and health literacy). Participants must also be 18 years old or older with sufficient proficiency in French or English to complete the interviews and questionnaires. In households in which both parents smoke, only one will be eligible to participate, but smoking cessation information will be offered to both. Families presenting at the clinic for an urgent medical issue are not eligible to participate.\n\nIntervention: Participants will be divided into control group (care as usual with CanCEASE at the end of the study period) and intervention (CanCEASE + Health navigator). All participants will complete questionnaires at Baseline, 6 and 12 months. The intervention group will receive CanCEASE at the end of each questionnaire. Controls will receive CanCEASE at 12 months. The intervention group will have the possibility to meet with the HNs and will be invited to commit to at least two sessions (i.e.: evaluation and a follow up), with the option to book more time as needed.\n\nAims and hypotheses: Examining how effective the combination of CanCEASE with HN support is in helping parents with unmet social needs quit smoking. Investigators will also examine the effects of the intervention on status of unmet social needs, if the intervention was implemented as planned and well accepted by clinics and participants, and what is the cost of the intervention for each person who quits smoking.",[152,29],[354,355,356,357,358],"Smoking cessation","Social risk","Second hand smoke","Health navigator","Unmet social needs","2024-10-21",{"date":361,"type":43},"2024-10-23",{"date":363,"type":20},"2025-03-01",{"date":365,"type":20},"2030-12",{"name":367,"class":83},"St. Justine's Hospital",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":92,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":228},"100476735","phase-1-adapting-and-evaluating-a-tobacco-use-cessation-program-for-people-living-with-hiv-in-uganda-and-zambia-100476735","NCT05487807","Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia","Quit4Life+: Adapting and Evaluating a Phone-Based Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia (Quit4Life+ )","Quit4Life","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Females who are pregnant, planning to get pregnant, or breastfeeding\n* \\\u003C18 years (underage of consent)\n* Visitor, not receiving continuous care at study site\n* Not a current daily tobacco user\n* Any physical, cognitive, or psychological disabilities that would prevent them from participating in the study\n* Illiterate in English and\u002For local languages\n* Does not consent",{"count":377,"type":20},800,[238],"This proposal tests the efficacy of a phone-based tobacco cessation intervention for people living with HIV (PLWH) in comparison to the standard of care (brief advice to quit) and nicotine replacement therapy (nicotine patches) in Uganda and Zambia. This study will provide insight into the efficacy, feasibility, applicability, and affordability of delivering tobacco cessation interventions through health care professionals at HIV treatment centers in two countries with different tobacco use patterns, policy environments, and health care resources. The previously tested SMS-platform to be used in this study is uniquely positioned to be scaled in low- and middle-income countries worldwide, in which case rigorous research showing even modest success in reducing the prevalence of tobacco consumption among PLWH could confer substantial health and economic benefits.",[381,29],"Nicotine Dependence","2023-11-27",{"date":384,"type":43},"2023-11-28",{"date":386,"type":43},"2023-09-13",{"date":388,"type":20},"2026-08-31",{"name":390,"class":83},"University of Southern California"]